title: Limited use for dual treatment with boosted protease inhibitors plus lamivudine in first-line antiretroviral therapy.
authors.affiliation: Desmond Tutu HIV Foundation, Institute of Infectious Disease and Molecular Medicine, University of Cape Town, Cape Town 7925, South Africa. Electronic address: catherine.orrell@hiv-research.org.za.
authors.forename: Catherine
authors.initials: C
authors.lastname: Orrell
authors.affiliation: Desmond Tutu HIV Foundation, Institute of Infectious Disease and Molecular Medicine, University of Cape Town, Cape Town 7925, South Africa.
authors.forename: Richard
authors.initials: R
authors.lastname: Kaplan
mesh_terms: D019380:Anti-HIV Agents / Q000627:therapeutic use*; D005260:Female; D015658:HIV Infections / Q000188:drug therapy*; D017320:HIV Protease Inhibitors / Q000627:therapeutic use*; D015497:HIV-1; D006801:Humans; D008297:Male; D012367:RNA, Viral / Q000097:blood*; D018894:Reverse Transcriptase Inhibitors / Q000627:therapeutic use*
chemical_list: D019380:Anti-HIV Agents; D017320:HIV Protease Inhibitors; D012367:RNA, Viral; D018894:Reverse Transcriptase Inhibitors